Trial
NCT01998035
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Columbia University
Collaborators
Celgene
Condition
Lymphoid Malignancies
Intervention
RomiDEPsin 10 MG/M2
Why stopped
PI left institution
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-22